CFM
CHRS icon

Catalyst Funds Management’s Coherus Oncology CHRS Stock Holding History

Catalyst Funds Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-56,600
Closed -$135K – 1233
2024
Q1 		$135K Buy
+56,600
New +$139K 0.04% 340

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Funds Management's CHRS Position: Q2 2024 in Review

Catalyst Funds Management sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 56,600 shares — an estimated $135K sold.

Catalyst Funds Management first reported a position in CHRS in Q1 2024 and held it in 1 quarter. The position peaked at $135K in Q1 2024. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

  • Catalyst Funds Management reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 56,600 Coherus Oncology shares in Q2 2024, an estimated $135K.
  • Catalyst Funds Management first reported a position in Coherus Oncology in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Coherus Oncology position peaked at $135K in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.